ArticleJournal of thoracic disease2026
Construction and validation of an acute exacerbation risk score for fibrotic idiopathic interstitial pneumonia.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute exacerbation (AE) of fibrotic idiopathic interstitial pneumonia (f-IIP) is a severe complication associated with high short-term mortality, yet standardized AE prediction tools remain limited. This study aimed to develop and internally validate a clinically accessible risk scoring system for predicting AE in patients with f-IIP. Methods: This single-centre retrospective cohort study enrolled 638 patients with f-IIP, including 358 patients with idiopathic pulmonary fibrosis (IPF) and 280 with other f-IIPs. A nomogram and simplified risk score were developed based on independent predictors identified by multivariate Cox regression. Internal validation using 1,000 bootstrap resamples was performed to evaluate discrimination, calibration, and clinical utility. Subgroup analyses were conducted for IPF and other f-IIP patients. Results: Multivariate Cox analysis identified six independent predictors of AE: age, diffusing capacity of the lung for carbon monoxide percent predicted (DLCO %pred), forced vital capacity percent predicted (FVC %pred), minimum oxygen saturation during the 6-minute walk test (6MWT Min SpO Conclusions: This multidimensional risk scoring system showed good predictive performance for AE in f-IIP and may support individualized risk stratification and clinical monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.